• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Intercure Ltd.

    12/18/25 5:15:10 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INCR alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

     

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the month of December 2025

     

    Commission File Number: 001-40614

     

    INTERCURE LTD.

    (Translation of registrant’s name into English)

     

    85 Medinat ha-Yehudim Street

    Herzliya, 4676670, Israel

    Tel: +972 77 460 5012

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    On December 15, 2025, InterCure Ltd. (dba Canndoc) (the “Company”) became aware that the Bazelet group of companies, a leading producer of cannabis oil (“Bazelet”), has initiated restructuring proceedings before the Israeli District Court, including an application for a temporary stay of proceedings.

     

    Bazelet is a service provider of the Company for production, EU-GMP-certified export, and distribution services in the Israeli market. In addition, Bazelet purchases raw materials and products from the Company from time to time.

     

    The Company holds checks issued by Bazelet in an aggregate amount of approximately NIS 27 million, which remain outstanding during the stay of proceedings.

     

    The Company is monitoring developments in this matter and reviewing the relevant court filings, and, in accordance with the instruction of the Company’s Board of Directors, plans to pursue appropriate legal actions to protect and preserve its rights and interests, and is evaluating collaboration with an additional packaging facility.

     

    Forward-Looking Statements

     

    This Report on Form 6-K contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements may include, but are not limited to, the status of Bazelet’s restructuring proceedings, the evaluation of alternative service providers and the Company’s plans to pursue legal actions, as well as statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: the outcome of Bazelet’s restructuring, the availability of alternative service providers, changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future. 

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      INTERCURE LTD.
       
    Date: December 18, 2025 /s/ Amos Cohen
      Amos Cohen
      Chief Financial Officer

     

     

     

     

    Get the next $INCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCR

    DatePrice TargetRatingAnalyst
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    More analyst ratings

    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation

    Agreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) ("InterCure" or the "Company") today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. ("Cannasoul"), a globally recognized pioneer in cannabis research and analytics

    11/3/25 8:30:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow

    The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YORK and HERZLIYA, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced its financial and operating results for the first half of 2025. Al

    10/8/25 9:02:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

    Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as Trump administration confirms it is exploring cannabis rescheduling, creating unprecedented potential opportunities for international operators like InterCure InterCure encouraged by recent regulatory momentum and positioned to capitalize on evolving U.S. cannabis landscape NEW YORK & HERZLIYA, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the strategic acquisition of Botanico Ltd., also

    9/19/25 8:47:55 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InterCure upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

    5/18/22 7:21:05 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    SEC Filings

    View All

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    12/18/25 5:15:10 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    11/25/25 4:05:04 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    11/3/25 8:40:18 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Financials

    Live finance-specific insights

    View All

    InterCure Reschedules 2022 Full Year Results Conference Call

    NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9

    4/3/23 3:27:01 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

    Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High

    3/31/23 8:00:49 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Reports Record Breaking Second Quarter Financial Results

    Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results

    8/15/22 9:15:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Intercure Ltd.

    SC 13G - Intercure Ltd. (0001857030) (Subject)

    5/16/22 1:02:53 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care